Scarica l'app Stockscreener
28.50
2.16%
-0.615
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
RSI Check: Should you avoid TG Therapeutics Inc stock right nowQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt - 富途牛牛
TG Therapeutics stock maintains Buy rating at B.Riley on strong Briumvi growth - Investing.com India
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - AOL.com
JP Morgan Adjusts Price Target for TGTX, Maintains Overweight Ra - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price - MarketBeat
TG Therapeutics, Inc. (TGTX) Investor Outlook: Exploring the 52.42% Potential Upside and Strategic Positioning in Biotechnology - DirectorsTalk Interviews
Quarterly Trades: Will TG Therapeutics Inc benefit from AI trendsWeekly Gains Report & Fast Momentum Entry Tips - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Readies New BRIUMVI Data As Market Weighs Valuation - Sahm
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Weakness And BRIUMVI Growth Assumptions - Yahoo Finance
TG Therapeutics to present BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Canada
TG Therapeutics to present BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
BRIUMVI multiple sclerosis data to headline San Diego ACTRIMS forum - Stock Titan
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with 43.77% Potential Upside - DirectorsTalk Interviews
Understanding Momentum Shifts in (TGTX) - Stock Traders Daily
TG Therapeutics Achieves 8.54% Return; Birkenstock Reports -31.21% Loss - Markets Mojo
Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX) - The Globe and Mail
Is TG Therapeutics (TGTX) Pricing Reflecting Its Strong DCF And P/E Valuation Signals? - Sahm
Why TG Therapeutics (TGTX) Is Up 6.9% After Issuing 2026 BRIUMVI-Centric Revenue Guidance And What's Next - Sahm
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Moving Averages: Should you avoid TG Therapeutics Inc stock right nowJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
Goldman Sachs Raises Price Target for TG Therapeutics (TGTX) to $39 | TGTX Stock News - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Trading 7.5% HigherHere's Why - MarketBeat
TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) - Seeking Alpha
HC Wainwright Forecasts TG Therapeutics FY2025 Earnings - MarketBeat
TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook - The Globe and Mail
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries - Intellectia AI
TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities - The Globe and Mail
TG Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - MarketBeat
TG Therapeutics Soars on Strong Revenue Guidance and BRIUMVI Mom - GuruFocus
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpTime to Buy? - MarketBeat
TGTX Stock Surges Over 12% Amid Positive Market Movement - GuruFocus
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics shares hit highest since November, last up 12.9% after prelim 2025 sales top estimate - marketscreener.com
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? - Asianet Newsable
Why TG Therapeutics Stock Is Moving Today - Benzinga
TG Therapeutics steigert Umsatzprognose für 2026 und übertrifft Umsatzprognose für 2025 - TradingView — Track All Markets
TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat - TradingView — Track All Markets
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Tumble Ahead Of SC Ruling On Trump's Tariffs— Wells Fargo, BP, WeRide In Focus (UPDATED) - Benzinga
Retail traders are piling into TG Therapeutics – what’s driving the chatter? - MSN
In the Wake of TG Therapeutics, Inc.'s (NASDAQ:TGTX) Latest US$225m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - Futubull
Avoiding Lag: Real-Time Signals in (TGTX) Movement - Stock Traders Daily
SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Menafn
Bank of America, Citigroup And 3 Stocks To Watch Heading Into Wednesday - Benzinga
TG Therapeutics reports $616 million in preliminary 2025 revenue By Investing.com - Investing.com Nigeria
TG Therapeutics Stock Pre-Market (+7.0%) : Strong 2026 Revenue Guidance Issued - Trefis
TG Therapeutics Looks To ENHANCE Growth With Pivotal 2026 Trial Readout - RTTNews
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally - Stocktwits
TG Therapeutics (TGTX) Projects Strong Revenue Growth for 2026 - GuruFocus
TGTX Sets 2026 Expense Forecast Amid New Developments - GuruFocus
TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26 - Intellectia AI
0.65%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):